Table 2. Selected ongoing clinical... | American Society of Hematology

Table 2.

Selected ongoing clinical trials with novel agents in patients with WM

ClinicalTrials.Gov ID	Agents	Mechanism of action	Phase
NCT04263480	Ibrutinib Carfilzomib	BTK inhibitor Proteasome inhibitor	3
NCT04263480	Ibrutinib	BTK inhibitor	3
NCT04061512	Ibrutinib Rituximab	BTK inhibitor Anti-CD20 mAb	2/3
NCT04061512	Cyclophosphamide Rituximab Dexamethasone	Alkylating agent Anti-CD20 mAb Steroid	2/3
NCT03506373	Ibrutinib Ixazomib	BTK inhibitor Proteasome inhibitor	2
NCT03620903	Ibrutinib Bortezomib Rituximab	BTK inhibitor Proteasome inhibitor Anti-CD20 mAb	2
NCT04273139	Ibrutinib Venetoclax	BTK inhibitor BCL2 antagonist	2
NCT03679624	Ibrutinib Daratumumab	BTK inhibitor Anti-CD38 mAb	2
NCT03187262	Daratumumab	Anti-CD38 mAb	2
NCT03630042	Pembrolizumab Rituximab	Anti-PD1 mAb Anti-CD20 mAb	2
NCT02962401	Idelalisib Obinutuzumab	PI3K inhibitor Anti-CD20 mAb	2
NCT03364231	Umbralisib	PI3K inhibitor	2
NCT03225716	Ibrutinib Ulocuplumab	BTK inhibitor Anti-CXCR4 mAb	1/2
NCT02457559	Tirabrutinib	BTK inhibitor	1/2
NCT03037645	Vecabrutinib	BTK inhibitor	1/2
NCT03162536	ARQ-351	BTK inhibitor	1/2
NCT03740529	LOXO-305	BTK inhibitor	1/2
NCT04274738	Ibrutinib Mavorixafor	BTK inhibitor CXCR4 antagonist	1
NCT04115059	Dasatinib	HCK inhibitor	Pilot

ClinicalTrials.Gov ID	Agents	Mechanism of action	Phase
NCT04263480	Ibrutinib Carfilzomib	BTK inhibitor Proteasome inhibitor	3
NCT04263480	Ibrutinib	BTK inhibitor	3
NCT04061512	Ibrutinib Rituximab	BTK inhibitor Anti-CD20 mAb	2/3
NCT04061512	Cyclophosphamide Rituximab Dexamethasone	Alkylating agent Anti-CD20 mAb Steroid	2/3
NCT03506373	Ibrutinib Ixazomib	BTK inhibitor Proteasome inhibitor	2
NCT03620903	Ibrutinib Bortezomib Rituximab	BTK inhibitor Proteasome inhibitor Anti-CD20 mAb	2
NCT04273139	Ibrutinib Venetoclax	BTK inhibitor BCL2 antagonist	2
NCT03679624	Ibrutinib Daratumumab	BTK inhibitor Anti-CD38 mAb	2
NCT03187262	Daratumumab	Anti-CD38 mAb	2
NCT03630042	Pembrolizumab Rituximab	Anti-PD1 mAb Anti-CD20 mAb	2
NCT02962401	Idelalisib Obinutuzumab	PI3K inhibitor Anti-CD20 mAb	2
NCT03364231	Umbralisib	PI3K inhibitor	2
NCT03225716	Ibrutinib Ulocuplumab	BTK inhibitor Anti-CXCR4 mAb	1/2
NCT02457559	Tirabrutinib	BTK inhibitor	1/2
NCT03037645	Vecabrutinib	BTK inhibitor	1/2
NCT03162536	ARQ-351	BTK inhibitor	1/2
NCT03740529	LOXO-305	BTK inhibitor	1/2
NCT04274738	Ibrutinib Mavorixafor	BTK inhibitor CXCR4 antagonist	1
NCT04115059	Dasatinib	HCK inhibitor	Pilot

HCK, hematopoietic cell kinase; mAb, monoclonal antibody; PD1, programmed cell death protein 1; PI3K, phosphatidylinositol-3 kinase.